Therapy Areas: Autoimmune
Can-Fite Expands its Namodenoson Distribution Deal with CKD in South Korea with NASH Indication
25 February 2019 - - Israel-based biotechnology company Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI) has expanded its distribution agreement with Chong Kun Dang Pharmaceuticals (Korean Stock Exchange: 185750.KS) in South Korea, for the indication of non-alcoholic steatohepatitis, the company said.

CKD will receive exclusive rights to distribute Namodenoson for the treatment of NASH in addition to liver cancer in South Korea. CKD has agreed to pay Can-Fite USD 1m upfront upon signing, with up to an additional USD 5m upon achieving certain regulatory and sales milestones.

Can-Fite will also be entitled to a transfer price for delivering finished product to CKD.

This agreement with CKD marks Can-Fite's expansion of the original deal for another indication with CKD in South Korea.

Namodenoson is a small orally bioavailable drug that binds with high affinity and selectivity to the A3 adenosine receptor.

Namodenoson is being evaluated in Phase II trials for two indications, as a second line treatment for hepatocellular carcinoma, and as a treatment for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis.

A3AR is highly expressed in diseased cells whereas low expression is found in normal cells. This differential effect accounts for the excellent safety profile of the drug.

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI) is an advanced clinical stage drug development company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, inflammatory disease and sexual dysfunction.

The company's lead drug candidate, Piclidenoson, is currently in Phase III trials for rheumatoid arthritis and psoriasis.

Can-Fite's liver cancer drug, Namodenoson, is in Phase II trials for hepatocellular carcinoma, the most common form of liver cancer, and for the treatment of non-alcoholic steatohepatitis.

Namodenoson has been granted Orphan Drug Designation in the US and Europe and Fast Track Designation as a second line treatment for HCC by the US Food and Drug Administration.

Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma.

CF602, the company's third drug candidate, has shown efficacy in the treatment of erectile dysfunction in preclinical studies and the company is investigating additional compounds, targeting A3AR, for the treatment of sexual dysfunction.

These drugs have an excellent safety profile with experience in over 1,000 patients in clinical studies to date.
Login
Username:

Password: